{"entity":{"id":"nct05485948","kind":"trial","name":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","aka":[],"tldr":"A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","summary":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU is a phase 2 interventional study registered as NCT05485948 by PharmaEssentia, with 49 participants enrolled, started 2021-10-08 and due to reach its primary completion in 2022-09-07. Interventions recorded: Ropeginterferon alfa-2b.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05485948","url":"https://clinicaltrials.gov/study/NCT05485948"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":["pharmaessentia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05485948","phase":"2","setting":"A Phase II Single-Arm Multicenter Study to Access Efficacy and Safety of P1101 in Chinese Polycythemia Vera Patients Who Are Intolerant or Resistance to Hydroxyurea","sponsor":"PharmaEssentia","enrolled":49,"outcomes":[]},"route":"/trials/nct05485948/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"company":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"}]}}